Since many cancers activate VEGF-A expression and the great importance of VEGF in neovascularization has been emphasized, strategies to inactivate VEGF/VEGFR signaling have led to significant suppression of tumor angiogenesis and tumor growth (Ferrara and Alitalo, 1999; Brekken et al., 2000), including the anti-VEGF-A mAb bevacizumab (Ferrara et al., 2004), as well as two small molecule tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib (Chung et al., 2010). Here, VEGFA is linked to neoplasm.